Why the study?
Does perioperative beta-blocker therapy reduce perioperative cardiovascular morbidity and mortality in patients with or at risk of coronary artery diseases undergoing non-cardiac surgery?
Does perioperative beta-blocker therapy reduce perioperative cardiovascular morbidity and mortality in patients with or at risk of coronary artery diseases undergoing non-cardiac surgery?
Routine initiation of perioperative beta-blocker therapy using fixed-dose protocols is not justified due to increased risks of mortality and stroke, indicating a need to revise current clinical guidelines.
Cautions against routine perioperative beta-blocker initiation; leaves optimal patient selection and dosing open for targeted trials.
Perioperative beta-blocker therapy has been considered a mainstay of perioperative cardioprotection in patients with or at risk of coronary artery diseases. However, current recommendations for perioperative beta blockade are based mainly on the findings of trials with inadequate methodology and data analysis. The recently published results of the first adequately powered large controlled randomized trial on the efficacy and safety of perioperative beta-blocker therapy confirmed the benefit of such therapy on the perioperative incidence of non-fatal myocardial infarctions. However, such a benefit occurred at the expense of increased total mortality and increased incidence of stroke, negating any beneficial effect. A subsequently published meta-analysis confirmed, in large part, these findings. Given these recent publications, most of the current recommendations for perioperative beta-blocker therapy are no longer supported by evidence, therefore respective revision is needed.
No takes yet. Share an insight, caveat, or question.
Hans‐Joachim Priebe (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: